DK4058151T3 - Nyt salt af terphenylforbindelse - Google Patents
Nyt salt af terphenylforbindelseInfo
- Publication number
- DK4058151T3 DK4058151T3 DK20886261.5T DK20886261T DK4058151T3 DK 4058151 T3 DK4058151 T3 DK 4058151T3 DK 20886261 T DK20886261 T DK 20886261T DK 4058151 T3 DK4058151 T3 DK 4058151T3
- Authority
- DK
- Denmark
- Prior art keywords
- new salt
- terphenyl compound
- terphenyl
- compound
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934923P | 2019-11-13 | 2019-11-13 | |
| PCT/JP2020/042383 WO2021095835A1 (en) | 2019-11-13 | 2020-11-13 | Novel salt of terphenyl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4058151T3 true DK4058151T3 (da) | 2025-06-30 |
Family
ID=75912767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20886261.5T DK4058151T3 (da) | 2019-11-13 | 2020-11-13 | Nyt salt af terphenylforbindelse |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12419858B2 (da) |
| EP (2) | EP4058151B1 (da) |
| JP (2) | JP7379680B2 (da) |
| KR (2) | KR102825246B1 (da) |
| CN (2) | CN114828844A (da) |
| AU (2) | AU2020382379B2 (da) |
| BR (2) | BR112022009221A2 (da) |
| CA (2) | CA3157404A1 (da) |
| DK (1) | DK4058151T3 (da) |
| ES (1) | ES3034158T3 (da) |
| FI (1) | FI4058151T3 (da) |
| HU (1) | HUE072206T2 (da) |
| MX (2) | MX2022005812A (da) |
| PH (2) | PH12022551137A1 (da) |
| PL (1) | PL4058151T3 (da) |
| PT (1) | PT4058151T (da) |
| TW (2) | TWI874489B (da) |
| WO (2) | WO2021095835A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221555A1 (ja) | 2017-05-31 | 2018-12-06 | 大鵬薬品工業株式会社 | Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法 |
| CA3157404A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| WO2022214303A1 (en) | 2021-04-08 | 2022-10-13 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| TW202308991A (zh) * | 2021-05-11 | 2023-03-01 | 美商亞士德製藥公司 | 三苯化合物之固體形式 |
| KR20240065302A (ko) * | 2021-09-30 | 2024-05-14 | 다이호야쿠힌고교 가부시키가이샤 | 비페닐 화합물 및 면역 체크포인트 분자 조절제를 사용한 암에 대한 조합 요법 |
| CN118510763A (zh) * | 2021-10-26 | 2024-08-16 | 阿斯泰克斯制药公司 | 1-(3-氨基吡咯烷-1-羰基)-3,4-二苯基苯化合物的苯甲酸盐的制备方法 |
| EP4522137A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| KR20250109775A (ko) | 2022-11-24 | 2025-07-17 | 오리존 지노믹스 에스.에이. | 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합 |
| WO2024229073A1 (en) * | 2023-05-02 | 2024-11-07 | Otsuka Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801518D0 (sv) * | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US6225049B1 (en) | 1992-06-17 | 2001-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Human insulinoma-associated cDNA |
| CA2469649C (en) | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| US8163509B2 (en) | 2008-10-20 | 2012-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2010077624A1 (en) | 2008-12-09 | 2010-07-08 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| EP2419177A1 (en) | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| EP2560949B1 (en) | 2010-04-20 | 2015-12-02 | Università degli Studi di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
| CN104892525A (zh) | 2010-07-29 | 2015-09-09 | 奥瑞泽恩基因组学股份有限公司 | Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途 |
| ES2642170T3 (es) | 2011-05-16 | 2017-11-15 | Taiho Pharmaceutical Co., Ltd. | Método para seleccionar la quimioterapia para un paciente con cáncer gástrico utilizando combinación de fármacos de tegafur, gimeracilo y oteracilo potásico e inhibidor de EGFR |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| MX370567B (es) * | 2012-05-09 | 2019-12-17 | Cantex Pharmaceuticals Inc | Tratamiento de mielosupresion. |
| EP2968358A4 (en) | 2013-03-15 | 2016-08-10 | Ariad Pharma Inc | NOVEL CHOLINKINASE INHIBITORS |
| DK3030323T3 (da) | 2013-08-06 | 2019-07-15 | Imago Biosciences Inc | Kdm1a-inhibitorer til behandlingen af sygdom |
| US9266907B2 (en) | 2013-09-05 | 2016-02-23 | King Abdullah University Of Science And Technology | Tunable rare-earth fcu-metal-organic frameworks |
| DK3080100T3 (da) | 2013-12-11 | 2023-02-06 | Celgene Quanticel Res Inc | Hæmmere af lysinspecifik demethylase-1 |
| CA2936111C (en) | 2014-01-06 | 2023-03-14 | Algomedix, Inc. | Trpa1 modulators |
| CN106659914B (zh) | 2014-05-01 | 2020-06-19 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| SG10202008486SA (en) | 2014-09-05 | 2020-09-29 | Celgene Quanticel Research Inc | Inhibitors of lysine specific demethylase-1 |
| WO2016172010A1 (en) | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| AU2016360481B2 (en) * | 2015-11-27 | 2019-09-12 | Taiho Pharmaceutical Co., Ltd. | Novel biphenyl compound or salt thereof |
| WO2018136961A1 (en) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
| TWI727173B (zh) * | 2017-05-26 | 2021-05-11 | 日商大鵬藥品工業股份有限公司 | 使用有新穎聯苯化合物之抗腫瘤效果增強劑 |
| CN110740991B (zh) | 2017-05-26 | 2023-07-04 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
| WO2018221555A1 (ja) | 2017-05-31 | 2018-12-06 | 大鵬薬品工業株式会社 | Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法 |
| HRP20230210T1 (hr) | 2017-06-30 | 2023-04-14 | Celgene Corporation | Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida |
| WO2019075327A1 (en) | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| AU2018377852B2 (en) | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| EP3735243A4 (en) | 2018-01-02 | 2021-08-25 | Celgene Corporation | ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE |
| BR112022000484A2 (pt) | 2019-07-17 | 2022-03-08 | Summit Oxford Ltd | Processo de preparação de ridinilazol e formas cristalinas do mesmo |
| CA3157404A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| KR20220151637A (ko) | 2020-03-06 | 2022-11-15 | 셀젠 콴티셀 리서치, 인크. | Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합 |
-
2020
- 2020-11-13 CA CA3157404A patent/CA3157404A1/en active Pending
- 2020-11-13 PL PL20886261.5T patent/PL4058151T3/pl unknown
- 2020-11-13 AU AU2020382379A patent/AU2020382379B2/en active Active
- 2020-11-13 CA CA3158442A patent/CA3158442A1/en active Pending
- 2020-11-13 HU HUE20886261A patent/HUE072206T2/hu unknown
- 2020-11-13 WO PCT/JP2020/042383 patent/WO2021095835A1/en not_active Ceased
- 2020-11-13 PT PT208862615T patent/PT4058151T/pt unknown
- 2020-11-13 FI FIEP20886261.5T patent/FI4058151T3/fi active
- 2020-11-13 TW TW109139799A patent/TWI874489B/zh active
- 2020-11-13 KR KR1020227019781A patent/KR102825246B1/ko active Active
- 2020-11-13 US US17/775,795 patent/US12419858B2/en active Active
- 2020-11-13 JP JP2022519478A patent/JP7379680B2/ja active Active
- 2020-11-13 MX MX2022005812A patent/MX2022005812A/es unknown
- 2020-11-13 EP EP20886261.5A patent/EP4058151B1/en active Active
- 2020-11-13 TW TW109139813A patent/TWI874490B/zh active
- 2020-11-13 US US17/775,800 patent/US20220387384A1/en active Pending
- 2020-11-13 MX MX2022005811A patent/MX2022005811A/es unknown
- 2020-11-13 DK DK20886261.5T patent/DK4058151T3/da active
- 2020-11-13 WO PCT/JP2020/042410 patent/WO2021095840A1/en not_active Ceased
- 2020-11-13 KR KR1020227019783A patent/KR20220113390A/ko active Pending
- 2020-11-13 BR BR112022009221A patent/BR112022009221A2/pt unknown
- 2020-11-13 CN CN202080079021.0A patent/CN114828844A/zh active Pending
- 2020-11-13 JP JP2022527859A patent/JP7492002B2/ja active Active
- 2020-11-13 AU AU2020382214A patent/AU2020382214B2/en active Active
- 2020-11-13 BR BR112022008020A patent/BR112022008020A2/pt unknown
- 2020-11-13 CN CN202080078991.9A patent/CN114728899B/zh active Active
- 2020-11-13 PH PH1/2022/551137A patent/PH12022551137A1/en unknown
- 2020-11-13 ES ES20886261T patent/ES3034158T3/es active Active
- 2020-11-13 EP EP20886658.2A patent/EP4058018A4/en active Pending
- 2020-11-13 PH PH1/2022/551169A patent/PH12022551169A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4058151T3 (da) | Nyt salt af terphenylforbindelse | |
| HUE059403T2 (hu) | Vegyületek | |
| IL283692A (en) | Novel composition | |
| DK3964969T3 (da) | Opdeling af soc-arkitektur | |
| DK3753185T3 (da) | Effektiv MAC-CE-angivelse af rumlig relation for semi-persistent SRS | |
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| IL286833A (en) | Compositions containing brazzein | |
| LT3883936T (lt) | Nauji heterocikliniai junginiai | |
| HUE049228T2 (hu) | Új kondenzált pirimidin vegyület vagy annak sója | |
| EP3922247A4 (en) | 15-PGDH INHIBITOR | |
| DK3833662T3 (da) | Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2- | |
| EP3909953A4 (en) | UPADACITINIB SALT COMPOUND AND METHOD FOR PREPARING IT | |
| DK3692039T3 (da) | Enantiomerer af substituerede thiazoler som antivirale forbindelser | |
| IL289831A (en) | Cartridge | |
| EP4021896A4 (en) | SALT | |
| DK3826982T3 (da) | Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer | |
| EP3746876A4 (en) | UNLOCKING CONSUMABLES | |
| EP4003986A4 (en) | Inhibitor compounds | |
| DK3808747T3 (da) | Imidazopyridinon-forbindelse | |
| DK3826983T3 (da) | Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere | |
| DK3749673T3 (da) | Krystallinsk form af bictegravir-natrium | |
| EP3829551C0 (en) | CRYSTALLINE EPINEPHRINE MALONATE SALT | |
| IL287177A (en) | Chiral indole compounds and their use | |
| IL280025A (en) | A xinafoate salt of a jak inhibiting compound |